Canada’s Federal Court of Appeal Limits Damages Available to Delayed Generics

June 08, 2009

Tags:

Food and Drug Regulatory Intellectual Property Intellectual Property Litigation Patents Pharmaceuticals

Related Expertise

Related Insights

Le gouvernement du Québec précise les exceptions concernant les programmes de soutien aux patients
Québec government finalizes exceptions for patient support programs
Canada’s PMPRB—amendments to fill the gap in jurisdiction for CSPs
2020 Year in Review—Canada’s Top 10 Drug and Vaccine Regulatory Updates
CUSMA: Canadian patent applications to be eligible for patent term adjustment for unreasonable prosecution delays

Back